Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Research & Development (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Research & Development for 4 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 12.7% to $7.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32.8 million through Dec 2025, down 3.82% year-over-year, with the annual reading at $32.8 million for FY2025, 3.82% down from the prior year.
  • Research & Development for Q4 2025 was $7.5 million at Phathom Pharmaceuticals, up from $7.0 million in the prior quarter.
  • The five-year high for Research & Development was $19.0 million in Q3 2022, with the low at $7.0 million in Q3 2025.
  • Average Research & Development over 4 years is $11.8 million, with a median of $10.5 million recorded in 2023.
  • The sharpest move saw Research & Development plummeted 42.21% in 2024, then increased 23.05% in 2025.
  • Over 4 years, Research & Development stood at $15.9 million in 2022, then decreased by 16.0% to $13.4 million in 2023, then plummeted by 35.92% to $8.6 million in 2024, then dropped by 12.7% to $7.5 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $7.5 million, $7.0 million, and $9.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.